BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31337550)

  • 1. Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension.
    Yamamoto K; Nishimura R; Kato F; Naito A; Suda R; Sekine A; Jujo T; Shigeta A; Sakao S; Tanabe N; Tatsumi K
    Int J Cardiol; 2020 Jan; 299():263-270. PubMed ID: 31337550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
    Ying M; Song J; Gu S; Zhao R; Li M
    Medicine (Baltimore); 2021 Jun; 100(22):e26211. PubMed ID: 34087896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
    Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.
    Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M
    Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty.
    Minatsuki S; Hatano M; Kiyosue A; Saito A; Maki H; Takimoto E; Komuro I
    Int Heart J; 2018 Sep; 59(5):1186-1188. PubMed ID: 30158388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
    Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
    Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
    Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
    Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
    Gratsianskaya SE; Valieva ZS; Martynyuk TV
    Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.